What question did this study set out to answer?

To report a case of life-threatening interstitial lung disease induced by Mirvetuximab treatment in a patient with metastatic uterine cancer.

A41-05 From Treatment to Trauma: A Case of Mirvetuximab-Soravtansine Induced Interstitial Lung Disease

View Full Paper

Ask AI

Bookmark

Authors

Case report reveals life-threatening interstitial lung disease in a patient treated with Mirvetuximab, suggesting vigilance for drug toxicity.

To report a case of life-threatening interstitial lung disease induced by Mirvetuximab treatment in a patient with metastatic uterine cancer.
Case report of an 80-year-old female with metastatic uterine cancer on Mirvetuximab presenting with hypoxia and lung infiltrates.
Evaluation through chest imaging and bronchoalveolar lavage for diagnosis of drug-induced ILD.
Patient received broad-spectrum antibiotics and intravenous steroids following diagnosis.
Patient exhibited progressive dyspnea and bilateral lung infiltrates suggestive of organizing pneumonia.
Bronchoalveolar lavage showed lymphocyte predominance and increased CD8+ count.
Condition deteriorated, leading to hospice care after failure to improve.

Valiveti et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Case report reveals life-threatening interstitial lung disease in a patient treated with Mirvetuximab, suggesting vigilance for drug toxicity.